Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus documentMarieke Biegstraaten, Carla E. M. Hollak, João Paulo Oliveira et al.|Orphanet Journal of Rare Diseases|2015Cited by 345
Maximum inspiratory pressure as a clinically meaningful trial endpoint for neuromuscular diseases: a comprehensive review of the literatureBenedikt Schoser, Peter Young, Tarekegn Geberhiwot et al.|Orphanet Journal of Rare Diseases|2017Cited by 109
Challenges in diagnosing and managing adult patients with urea cycle disordersKarolina M. Stępień, Eileen P. Treacy, Tarekegn Geberhiwot et al.|Journal of Inherited Metabolic Disease|2019Cited by 55
Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in EnglandMaureen Cleary, Karolina M. Stępień, Tarekegn Geberhiwot et al.|Orphanet Journal of Rare Diseases|2021Cited by 29